Published: 30 November 2021
Author(s): Francesco Menichetti, Marco Falcone, Giusy Tiseo
Issue: January 2022
Section: Clinical Insights

Immunotherapy with convalescent plasma (CP) has been used in the past in several infectious diseases (influenza, SARS, MERS) with the aim to shorten or stop the phase of viral replication and to improve the patient outcome. However, a clear benefit was never demonstrated.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.